北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients
作者: Kush, Debra1; Hu, Da-Yi2; Ye, Ping3; Kim, Hyo-Soo4; Chen, Erluo; Sirah, Waheeda; Sisk, Christine McCrary; Paolini, John F.; Maccubbin, Darbie
关键词: Extended-release niacin ; Flushing ; Laropiprant
刊名: CARDIOLOGY
发表日期: 2009
DOI: 10.1159/000228585
卷: 114, 期:3, 页:192-198
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: NICOTINIC-ACID ; PRIMARY HYPERCHOLESTEROLEMIA ; CORONARY-DISEASE ; NIACIN NIASPAN ; LONG-TERM ; EFFICACY ; DYSLIPIDEMIA ; TOLERABILITY ; CHOLESTEROL ; LOVASTATIN
英文摘要:

Objective: Niacin is underutilized due to flushing, which occurs in over 90% of niacin-treated patients. Laropiprant (LRPT) reduces flushing associated with niacin. This study compared flushing with a combination tablet of extended-release (ER) niacin (ERN)/LRPT to niacin ER (N-ER; without LRPT) during the first week of therapy among patients in Asia. Methods: Following a 1-week placebo run-in, 332 patients with dyslipidemia from China, Korea and Singapore were randomized to ERN/LRPT 1 g/20 mg, N-ER 1 g (given as Niaspan (R)) or placebo in a 2: 2: 1 ratio for 1 week. Patient-reported flushing severity was assessed using the Global Flushing Severity Score (GFSS; none/mild = 0-3; moderate = 4-6; severe = 7-9; extreme = 10). Results: Compared with N-ER, the ERN/LRPT group experienced significantly less flushing (p < 0.001), as measured by maximum GFSS categorized as none/mild, moderate, severe or extreme. Overall, 23.8% of patients in the ERN/LRPT group and 50.0% in the N-ER group (p < 0.001), versus 12.1% in the placebo group, had moderate or greater flushing (GFSS >= 4). Except for flushing, which occurred more frequently in the N-ER group, ERN/LRPT had a safety/tolerability profile similar to that of N-ER. Conclusion: ERN/LRPT produced significantly less flushing than N-ER during the initiation of therapy and was generally well tolerated in Asian patients with dyslipidemia. Copyright (C) 2009 S. Karger AG, Basel

语种: 英语
项目资助者: Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA
WOS记录号: WOS:000270364900006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55036
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Merck & Co Inc, Merck Res Labs, Cardiovasc Dis, Rahway, NJ 07065 USA
3.Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
4.Seoul Natl Univ Hosp, Seoul 110744, South Korea

Recommended Citation:
Kush, Debra,Hu, Da-Yi,Ye, Ping,et al. Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients[J]. CARDIOLOGY,2009,114(3):192-198.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Kush, Debra]'s Articles
[Hu, Da-Yi]'s Articles
[Ye, Ping]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Kush, Debra]‘s Articles
[Hu, Da-Yi]‘s Articles
[Ye, Ping]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace